AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVXS
CUSIPN/A
Phone847-572-8280
Debt
Debt-to-Equity RatioN/A
Current Ratio8.22
Quick Ratio8.22
Price-To-Earnings
Trailing P/E Ratio-29.92
Forward P/E Ratio-22.48
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$15.46 per share
Price / Book14.09
Profitability
EPS (Most Recent Fiscal Year)($7.28)
Net Income$-218,050,000.00
Net MarginsN/A
Return on Equity-93.95%
Return on Assets-83.75%
Miscellaneous
Employees219
Outstanding Shares36,820,000
Market Cap$8.02 billion
AveXis (NASDAQ:AVXS) Frequently Asked Questions
What is AveXis' stock symbol?
AveXis trades on the NASDAQ under the ticker symbol "AVXS."
How were AveXis' earnings last quarter?
AveXis (NASDAQ:AVXS) posted its earnings results on Wednesday, May, 9th. The company reported ($6.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.32) by $2.88. View AveXis' Earnings History.
What price target have analysts set for AVXS?
18 Wall Street analysts have issued 12 month price objectives for AveXis' shares. Their forecasts range from $52.00 to $171.00. On average, they anticipate AveXis' stock price to reach $124.7778 in the next twelve months. This suggests that the stock has a possible downside of 42.7%. View Analyst Price Targets for AveXis.
What is the consensus analysts' recommendation for AveXis?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AveXis in the last year. There are currently 1 sell rating, 12 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AveXis.
What are Wall Street analysts saying about AveXis stock?
Here are some recent quotes from research analysts about AveXis stock:
- 1. According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (5/7/2018)
- 2. William Blair analysts commented, "We believe that other companies may begin to follow suit and see this as a positive for other AAV companies, most notably in our coverage, Spark (ONCE $62.06; Outperform) and Audentes (BOLD $28.11; Outperform)." (4/9/2018)
- 3. Mizuho analysts commented, "We expect a pre-BLA meeting in 2Q/3Q18, and potential regulatory approval in 2019 for type 1 SMA. We also see additional upside for AVXS-101 in SMA type 2 patients. KeyPoints Gene therapy is coming of age. After years of advancements and discovery in the field of gene therapy, we believe a number of companies are on the cusp of gaining approval for these novel one-time treatments. We see strong potential for leading candidate products and take confidence from the recent unanimous FDA approval of Spark’s (ONCE, Buy, $79 PT) Luxturna. A significant opportunity for gene therapy in the treatment of SMA. With approximately 60% of the incident SMA population affected by type 1 and limited treatment options, AveXis’ lead product candidate AVXS-101 could have a substantial impact. Given strong data from a recent phase 1 trial, we believe AVXS-101 could capture a significant market share in SMA type 1." (2/12/2018)
- 4. Chardan Capital analysts commented, "We would encourage buying on any AVXS weakness today, on the potential that the market may have understandably misunderstood what could be an atypical but stepped up process in terms of filing timelines for AVXS-101 in SMA type 1. Our take: Our base case (see our 15 June 2017 note) of a filing after pivotal STR1VE (NCT03306277) phase III data seems to have been improved upon. There are reasons to believe AveXis could file AVXS-101 by 3Q18, with a blue skies" scenario involving AVXS-101 approval by end-2018 or early-2019. We note AveXis’ appropriately non-promotional commentary when executing its duties in communicating status of important regulatory matters to the market." (1/5/2018)
Who are some of AveXis' key competitors?
Some companies that are related to AveXis include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN) and Repligen (RGEN).
Who are AveXis' key executives?
AveXis' management team includes the folowing people:
- Mr. Sean P. Nolan, Chief Exec. Officer, Pres and Director (Age 50)
- Dr. Sukumar Nagendran M.D., Chief Medical Officer and Sr. VP (Age 51)
- Mr. Phillip B. Donenberg CPA, Sr. VP, CFO & Principal Accounting Officer (Age 57)
- Mr. Brian K. Kaspar Ph.D., Chief Scientific Officer, Director and Member of Scientific Advisory Board (Age 44)
- Mr. Michael B. Johannesen, Chief Compliance Officer, Sr. VP and Gen. Counsel (Age 52)
When did AveXis IPO?
(AVXS) raised $86 million in an initial public offering on Thursday, February 11th 2016. The company issued 4,300,000 shares at $19.00-$21.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.
Has AveXis been receiving favorable news coverage?
News stories about AVXS stock have trended somewhat positive on Tuesday, Accern reports. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AveXis earned a coverage optimism score of 0.00 on Accern's scale. They also gave media stories about the company an impact score of 46.95 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for AveXis.
How do I buy shares of AveXis?
Shares of AVXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AveXis' stock price today?
One share of AVXS stock can currently be purchased for approximately $217.83.
How big of a company is AveXis?
AveXis has a market capitalization of $8.02 billion. The company earns $-218,050,000.00 in net income (profit) each year or ($7.28) on an earnings per share basis. AveXis employs 219 workers across the globe.
How can I contact AveXis?
AveXis' mailing address is 2275 HALF DAY ROAD SUIT 200, BANNOCKBURN IL, 60015. The company can be reached via phone at 847-572-8280 or via email at [email protected]
MarketBeat Community Rating for AveXis (NASDAQ AVXS)
MarketBeat's community ratings are surveys of what our community members think about AveXis and other stocks. Vote "Outperform" if you believe AVXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
